Van Berkom & Associates Inc. bought a new stake in Option Care Health, Inc. (NASDAQ:OPCH – Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,587,636 shares of the company’s stock, valued at approximately $42,739,000.
Other hedge funds have also made changes to their positions in the company. Royal Bank of Canada grew its position in Option Care Health by 20.7% during the first quarter. Royal Bank of Canada now owns 231,161 shares of the company’s stock valued at $8,078,000 after purchasing an additional 39,661 shares in the last quarter. AQR Capital Management LLC increased its stake in Option Care Health by 162.6% in the 1st quarter. AQR Capital Management LLC now owns 41,633 shares of the company’s stock valued at $1,450,000 after buying an additional 25,777 shares during the period. Empowered Funds LLC purchased a new stake in Option Care Health in the 1st quarter worth approximately $208,000. Invesco Ltd. lifted its position in Option Care Health by 2.7% in the 2nd quarter. Invesco Ltd. now owns 294,363 shares of the company’s stock worth $9,561,000 after buying an additional 7,678 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Option Care Health by 528.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,407 shares of the company’s stock valued at $46,000 after buying an additional 1,183 shares during the period. 98.05% of the stock is owned by hedge funds and other institutional investors.
Option Care Health Price Performance
NASDAQ OPCH opened at $21.74 on Monday. The company has a quick ratio of 1.07, a current ratio of 1.64 and a debt-to-equity ratio of 0.85. The stock has a market capitalization of $3.41 billion, a PE ratio of 16.85, a price-to-earnings-growth ratio of 1.21 and a beta of 0.65. Option Care Health, Inc. has a 12-month low of $18.01 and a 12-month high of $36.80. The company has a 50 day moving average price of $21.15 and a two-hundred day moving average price of $27.46.
Analyst Upgrades and Downgrades
Several research firms have recently commented on OPCH. Stephens restated an “equal weight” rating and set a $24.00 price target (down from $30.00) on shares of Option Care Health in a report on Friday. JPMorgan Chase & Co. cut their price objective on Option Care Health from $40.00 to $33.00 and set an “overweight” rating for the company in a report on Monday, May 4th. TD Cowen reduced their price objective on Option Care Health from $37.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, May 1st. Weiss Ratings downgraded Option Care Health from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 11th. Finally, The Goldman Sachs Group began coverage on Option Care Health in a research note on Monday, June 8th. They issued a “neutral” rating and a $22.00 target price on the stock. Eight analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.08.
Read Our Latest Stock Report on Option Care Health
Insider Buying and Selling
In other Option Care Health news, Director Timothy P. Sullivan acquired 24,154 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was purchased at an average cost of $20.69 per share, for a total transaction of $499,746.26. Following the completion of the acquisition, the director owned 73,383 shares of the company’s stock, valued at approximately $1,518,294.27. This trade represents a 49.06% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO John Charles Rademacher bought 12,500 shares of the stock in a transaction on Monday, May 4th. The shares were acquired at an average cost of $21.18 per share, for a total transaction of $264,750.00. Following the completion of the transaction, the chief executive officer directly owned 695,152 shares of the company’s stock, valued at approximately $14,723,319.36. The trade was a 1.83% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 73,264 shares of company stock worth $1,548,316. Corporate insiders own 1.70% of the company’s stock.
Option Care Health Company Profile
Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.
Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.
See Also
- Five stocks we like better than Option Care Health
- Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
- Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises
- 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Want to see what other hedge funds are holding OPCH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Option Care Health, Inc. (NASDAQ:OPCH – Free Report).
Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.
